### AstraZeneca Shines at Major Oncology Conference Amid Broader Healthcare Discussions

CHICAGO - In a yearly tradition, 40,000 individuals in the fields of cancer research, medical practice, and the pharmaceutical industry convene in Chicago for the largest oncology meeting. Over the past seven years, one company has almost consistently taken center stage with its innovative medicines: AstraZeneca.

In a quieter setting far removed from the buzz of the American Society of Clinical Oncology's annual meeting, Pascal Soriot, the often combative CEO of AstraZeneca, expressed remarkable confidence. Speaking candidly in a wood-paneled conference room at the St. Regis Hotel, Soriot discussed not just the company's significant presentations, but also broader issues such as the Trump administration's initiatives on drug pricing, AstraZeneca's future prospects, and the public's reaction to Covid vaccines.

"So I think we can always be better, but I think we are in a good place today," Soriot remarked, smiling broadly. He highlighted that the essence of human nature is to never be fully satisfied, which is the driving force behind continual progress. "Human nature is to be dissatisfied, and that's how humanity progresses, right?"

His optimism suggested a secure and forward-looking position for AstraZeneca, cemented by years of pioneering contributions to oncology and resilience in the face of global healthcare challenges.